(Q24674561)

English

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

scientific article

In more languages

edit

Statements

0 references

1 reference

1 reference

Europe PubMed Central

title

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review (English)

0 references

main subject

sensory nervous system

0 references

1 reference

1 reference

Jillian Leigh Colquitt

series ordinal

2

object named as

J Colquitt

0 references

author name string

A L Takeda

series ordinal

1

0 references

A J Clegg

series ordinal

3

0 references

J Jones

series ordinal

4

0 references

language of work or name

English

0 references

publication date

September 2007

0 references

published in

British Journal of Ophthalmology

0 references

volume

91

0 references

issue

9

0 references

page(s)

1177-82

0 references

cites work

Ranibizumab for neovascular age-related macular degeneration

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

7 April 2017

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 September 2017

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 September 2017

Bevacizumab: a new way of doing business?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 September 2017

How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 September 2017

Is the incidence of registrable age-related macular degeneration increasing?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 September 2017

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 November 2018

Pegaptanib for neovascular age-related macular degeneration

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1954893

retrieved

28 November 2018

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/17475698

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1136/BJO.2007.118562

0 references

0 references

0 references

ResearchGate publication ID

6353908

0 references

(Q24674561)

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)